Monthly Archives: February 2011

Clinical Trial End Points At Different Phases of Clinical Development


Dr Michael Silverman of BioStrategics Consulting Ltd, reviews the type of clinical trial end points to use at different clinical development phases of a pharmaceutical product. In my last blog I talked about the general concept of clinical trial end … Continue reading

Posted in Clinical, Clinical studies, clinical trials | Tagged , , , , , , , , , , , , , | Leave a comment

Clinical Trial Efficacy End Points: What to choose?


Dr Michael Silverman of BioStrategics Consulting Ltd., reviews the use of efficacy end points in clinical trials and the needs of the different audiences, including corporate sponsors, scientists and academics, regulatory authorities and the consumer. The choice of clinical trial … Continue reading

Posted in clinical trials | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

3 Phase 1 Clinical Study Oncology Dilemmas for Sponsors


Dr Michael Silverman of BioStrategics Consulting Ltd discusses some of the dilemmas associated with Phase 1 clinical study design and implementation in the field of oncology and the impact on drug development. Many of you are knowledgeable about Phase 1 … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment

4 Missteps in Phase 2 Clinical Studies


Dr Michael Silverman of BioStrategics Consulting Ltd discusses some of the more common mistakes made in Phase 2 clinical study design and implementation. Every so often, I run into someone who sees Phase 2 clinical studies as an unnecessary stage … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , | Leave a comment